dc.creator | Dubner, Sergio | es |
dc.creator | Saraiva, José Francisco Kerr | es |
dc.creator | Fragoso, Juan Carlos Nunez | es |
dc.creator | Barón-Esquivias, Gonzalo | es |
dc.creator | Teutsch, Christine | es |
dc.creator | Gurusamy, Venkatesh Kumar | es |
dc.creator | Marler, Sabrina | es |
dc.creator | Huisman, Menno V. | es |
dc.creator | Lip, Gregory Y.H. | es |
dc.creator | Zeballos, Cecilia | es |
dc.date.accessioned | 2023-10-20T13:32:34Z | |
dc.date.available | 2023-10-20T13:32:34Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | Dubner, S., Saraiva, J.F.K., Fragoso, J.C.N., Barón-Esquivias, G., Teutsch, C., Gurusamy, V.K.,...,Zeballos, C. (2020). Effectiveness and safety of dabigatran in Latin American patients with atrial fibrillation: Two years follow up results from GLORIA-AF registry. IJC Heart and Vasculature, 31 (100666), 1-5. https://doi.org/http://doi.org/10.1016/j.ijcha.2020.100666. | |
dc.identifier.issn | 2352-9067 | es |
dc.identifier.uri | https://hdl.handle.net/11441/149817 | |
dc.description.abstract | Background: Real-world data from different regions are needed to support the external validity of con trolled trials and assess the impact of new oral anticoagulants (NOAC) in clinical practice.
Methods: ‘‘GLORIA-AF” is a large, ongoing, multicenter, global, prospective registry program in patients
with newly diagnosed non-valvular atrial fibrillation (NVAF) at risk of stroke. Newly diagnosed patients
with NVAF (within 4.5 months) and a CHA2DS2-VASc score 1 were consecutively enrolled. The study
objective was to estimate the incidence rate of stroke and major bleeding after a two year follow up of
patients on dabigatran that participated in the ‘‘GLORIA-AF” study (Phase II) in Latin America.
Results: Latin America included 378 eligible patients that received dabigatran in eight countries
(Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Perú, and Venezuela): 56.3% were male; mean age
was 70.3 ± 10.8 years; 43.4% had paroxysmal AF; 36.0% persistent AF and 20.6% permanent AF. Mean
CHA2DS2-VASc score was 3.2 ± 1.4; mean HAS-BLED score was 1.2 ± 0.8. Incidence rates for clinical events
after 2-years of follow-up per 100 patient-years were as follows: stroke 0.33 (95% CI: 0.04–1.17), major
bleeding 0.49 (95% CI: 0.10–1.42) and all-cause death 4.06 (95% CI: 2.63–6.00). Persistence with dabiga tran at 6, 12 and 24 months was 91%, 86%, and 80%, respectively.
Conclusion: These regional data shows the sustained safety and effectiveness of dabigatran over two
years of follow-up, consistent with already available evidence. An increase in accessibility and incorpo ration of NOAC to anticoagulant treatment strategies could potentially have a positive impact on AF
stroke prevention in Latin America. | es |
dc.format | application/pdf | es |
dc.format.extent | 5 p. | es |
dc.language.iso | eng | es |
dc.publisher | Elsevier | es |
dc.relation.ispartof | IJC Heart and Vasculature, 31 (100666), 1-5. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Non-valvular atrial fibrillation (NVAF) | es |
dc.subject | New oral anticoagulants (NOAC) | es |
dc.subject | Dabigatran | es |
dc.subject | Latin America (LA) | es |
dc.title | Effectiveness and safety of dabigatran in Latin American patients with atrial fibrillation: Two years follow up results from GLORIA-AF registry | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S235290672030364X?via%3Dihub | es |
dc.identifier.doi | http://doi.org/10.1016/j.ijcha.2020.100666 | es |
dc.journaltitle | IJC Heart and Vasculature | es |
dc.publication.volumen | 31 | es |
dc.publication.issue | 100666 | es |
dc.publication.initialPage | 1 | es |
dc.publication.endPage | 5 | es |